Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 08/26/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–08/25/2026 Record Record Date Vuga Group Change Status Recency Days Public Significance Score The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer 06/30/2015 INTERVENTIONAL unchanged 4,075.85 0 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma 07/01/2015 INTERVENTIONAL unchanged 4,074.85 0 A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer 07/02/2015 INTERVENTIONAL unchanged 4,073.85 0 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer 07/07/2015 INTERVENTIONAL unchanged 4,068.85 0 A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma 07/07/2015 INTERVENTIONAL unchanged 4,068.85 0 Management of Low-risk (Grade I and II) DCIS 07/08/2015 INTERVENTIONAL unchanged 4,067.85 0 Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer 07/10/2015 INTERVENTIONAL unchanged 4,065.85 0 White Adipose Tissue in Pregnancy Study 07/14/2015 OBSERVATIONAL unchanged 4,061.85 0 Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors 07/15/2015 INTERVENTIONAL unchanged 4,060.85 0 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer 07/20/2015 INTERVENTIONAL unchanged 4,055.85 0 Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities 07/31/2015 INTERVENTIONAL unchanged 4,044.85 0 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer 08/04/2015 INTERVENTIONAL unchanged 4,040.85 0 Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer 08/20/2015 OBSERVATIONAL unchanged 4,024.85 0 Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH 08/20/2015 INTERVENTIONAL unchanged 4,024.85 0 Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer 08/20/2015 OBSERVATIONAL unchanged 4,024.85 0 Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer 08/28/2015 INTERVENTIONAL unchanged 4,016.85 0 Preovulatory Uterine Flushing With Saline as a Treatment for Unexplained Infertility 09/03/2015 INTERVENTIONAL unchanged 4,010.85 0 Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer 09/04/2015 OBSERVATIONAL unchanged 4,009.85 0 Biomarker Guided Treatment in Gynaecological Cancer 09/07/2015 INTERVENTIONAL unchanged 4,006.85 0 Treatments for Urogynaecological Problems and Patient Selfreports 09/15/2015 OBSERVATIONAL unchanged 3,998.85 0 Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia 09/15/2015 INTERVENTIONAL unchanged 3,998.85 0 Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer 09/29/2015 INTERVENTIONAL unchanged 3,984.85 0 Effect of Brief-tele Support on Attendance at Physiotherapy Sessions 09/30/2015 INTERVENTIONAL unchanged 3,983.85 0 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65 10/01/2015 INTERVENTIONAL unchanged 3,982.85 0 Muscle Loss and Fatigue as a Consequence of Radiotherapy 10/05/2015 OBSERVATIONAL unchanged 3,978.85 0 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer 10/08/2015 INTERVENTIONAL unchanged 3,975.85 0 Uterine Transplantation for the Treatment of Uterine Factor Infertility 10/09/2015 INTERVENTIONAL unchanged 3,974.85 0 Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy 10/12/2015 INTERVENTIONAL unchanged 3,971.85 0 PIERS and BIS, sFIT:PIGF, Adrenomedullin 10/19/2015 OBSERVATIONAL unchanged 3,964.85 0 Toronto Gestational Glucose Tolerance Cohort 10/21/2015 OBSERVATIONAL unchanged 3,962.85 0 Investigating the Impact of Obesity on Pubertal Development in Girls 10/22/2015 OBSERVATIONAL unchanged 3,961.85 0 Beauty from Within Community Screening Project 10/28/2015 OBSERVATIONAL unchanged 3,955.85 0 Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis 10/28/2015 INTERVENTIONAL unchanged 3,955.85 0 Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors 10/30/2015 INTERVENTIONAL unchanged 3,953.85 0 Vasculitis Pregnancy Registry 11/02/2015 OBSERVATIONAL unchanged 3,950.85 0 AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE) 11/03/2015 OBSERVATIONAL unchanged 3,949.85 0 Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer 11/04/2015 INTERVENTIONAL unchanged 3,948.85 0 Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 11/04/2015 INTERVENTIONAL unchanged 3,948.85 0 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia 11/04/2015 INTERVENTIONAL unchanged 3,948.85 0 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. 11/05/2015 INTERVENTIONAL unchanged 3,947.85 0 Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device 11/09/2015 INTERVENTIONAL unchanged 3,943.85 0 Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery 11/10/2015 OBSERVATIONAL unchanged 3,942.85 0 Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) 11/16/2015 INTERVENTIONAL unchanged 3,936.85 0 [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer 11/18/2015 INTERVENTIONAL unchanged 3,934.85 0 Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial 11/20/2015 INTERVENTIONAL unchanged 3,932.85 0 THE INFLUENCE OF COGNITIVE BEHAVIORAL THERAPY IN SEXUAL DYSFUNCTION FEMALE: Randomized Clinical Trial 11/24/2015 INTERVENTIONAL unchanged 3,928.85 0 Tomosynthesis Mammographic Imaging Screening Trial 11/27/2015 INTERVENTIONAL unchanged 3,925.85 0 Women Informed to Screen Depending on Measures of Risk (Wisdom Study) 12/03/2015 INTERVENTIONAL unchanged 3,919.85 0 Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer 12/09/2015 INTERVENTIONAL unchanged 3,913.85 0 Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 12/11/2015 INTERVENTIONAL unchanged 3,911.85 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 08/26/2026 · upstream last modified 08/26/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Public Significance Score using the documented compute method. · methodology